Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Region, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Pulmonary Arterial Hypertension Market: Methodology and Scope
                   1.1. Market Segmentation and Scope
                   1.2. Market Definitions
                       1.2.1. Information Analysis
                       1.2.2. Market Formulation & Data Visualization
                       1.2.3. Data Validation & Publishing
                   1.3. Research Assumptions
                   1.4. Information Procurement
                       1.4.1. Primary Research
                   1.5. Information or Data Analysis
                   1.6. Market Formulation & Validation
                   1.7. Market Model
                   1.8. Global Market: CAGR Calculation
                   1.9. Objective
                       1.9.1. Objective 1
                       1.9.2. Objective2
Chapter 2. Pulmonary Arterial Hypertension Market: Executive Summary
                   2.1. Market Snapshot
                   2.2. Segment Snapshot
                   2.3. Competitive Landscape Snapshot
Chapter 3. Pulmonary Arterial Hypertension Market: Variables, Trends, & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Notable burden of pulmonary arterial hypertension
                           3.2.1.2. Supportive initiatives by public and private organizations
                           3.2.1.3. Supportive reimbursement policies
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Patent expiry of key drugs
                           3.2.2.2. Drug-related side effects
                       3.2.3. Market opportunity analysis
                       3.2.4. Market Challenge analysis
                   3.3. Industry Analysis Tools
                       3.3.1. Porter’s Five Forces Analysis
                       3.3.2. PESTEL Analysis
                   3.4. Disease Prevalence Analysis
                   3.5. Pipeline Analysis
                   3.6. Patent Expiry
                   3.7. Pricing Analysis
Chapter 4. Product & Service Business Analysis
                   4.1. Segment Dashboard
                   4.2. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
                   4.3. Endothelin Receptor Antagonists (ERAs)
                       4.3.1. Endothelin Receptor Antagonists (ERAs) Market, 2018 - 2030 (USD Million)
                   4.4. PDE-5 Inhibitors
                       4.4.1. PDE-5 Inhibitors Market, 2018 - 2030 (USD Million)
                   4.5. Prostacyclin and Prostacyclin Analogs
                       4.5.1. Prostacyclin and Prostacyclin Analogs Market, 2018 - 2030 (USD Million)
Chapter 5. Type Business Analysis
                   5.1. Segment Dashboard
                   5.2. Pulmonary Arterial Hypertension Market: Type Movement Analysis, 2023 & 2030 (USD Million)
                   5.3. Branded
                       5.3.1. Branded Market, 2018 - 2030 (USD Million)
                   5.4. Generic
                       5.4.1. Generic Market, 2018 - 2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
                   6.1. Segment Dashboard
                   6.2. Pulmonary Arterial Hypertension Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
                   6.3. Oral
                       6.3.1. Oral Market, 2018 - 2030 (USD Million)
                   6.4. Intravenous/ Subcutaneous
                       6.4.1. Intravenous/ Subcutaneous Market, 2018 - 2030 (USD Million)
                   6.5. Inhalational
                       6.5.1. Inhalational Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
                   7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
                   7.2. North America
                       7.2.1. North America Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.2.2. U.S.
                           7.2.2.1. Key Country Dynamics
                           7.2.2.2. Competitive Scenario
                           7.2.2.3. Regulatory Framework
                           7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.2.3. Canada
                           7.2.3.1. Key Country Dynamics
                           7.2.3.2. Competitive Scenario
                           7.2.3.3. Regulatory Framework
                           7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                   7.3. Europe
                       7.3.1. Europe Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.2. UK
                           7.3.2.1. Key Country Dynamics
                           7.3.2.2. Competitive Scenario
                           7.3.2.3. Regulatory Framework
                           7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.3. Germany
                           7.3.3.1. Key Country Dynamics
                           7.3.3.2. Competitive Scenario
                           7.3.3.3. Regulatory Framework
                           7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.4. France
                           7.3.4.1. Key Country Dynamics
                           7.3.4.2. Competitive Scenario
                           7.3.4.3. Regulatory Framework
                           7.3.4.4. France Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.5. Italy
                           7.3.5.1. Key Country Dynamics
                           7.3.5.2. Competitive Scenario
                           7.3.5.3. Regulatory Framework
                           7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.6. Spain
                           7.3.6.1. Key Country Dynamics
                           7.3.6.2. Competitive Scenario
                           7.3.6.3. Regulatory Framework
                           7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.7. Sweden
                           7.3.7.1. Key Country Dynamics
                           7.3.7.2. Competitive Scenario
                           7.3.7.3. Regulatory Framework
                           7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.8. Norway
                           7.3.8.1. Key Country Dynamics
                           7.3.8.2. Competitive Scenario
                           7.3.8.3. Regulatory Framework
                           7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.3.9. Denmark
                           7.3.9.1. Key Country Dynamics
                           7.3.9.2. Competitive Scenario
                           7.3.9.3. Regulatory Framework
                           7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                   7.4. Asia Pacific
                       7.4.1. Asia Pacific Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.4.2. Japan
                           7.4.2.1. Key Country Dynamics
                           7.4.2.2. Competitive Scenario
                           7.4.2.3. Regulatory Framework
                           7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.4.3. China
                           7.4.3.1. Key Country Dynamics
                           7.4.3.2. Competitive Scenario
                           7.4.3.3. Regulatory Framework
                           7.4.3.4. China Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.4.4. India
                           7.4.4.1. Key Country Dynamics
                           7.4.4.2. Competitive Scenario
                           7.4.4.3. Regulatory Framework
                           7.4.4.4. India Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.4.5. Australia
                           7.4.5.1. Key Country Dynamics
                           7.4.5.2. Competitive Scenario
                           7.4.5.3. Regulatory Framework
                           7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.4.6. Thailand
                           7.4.6.1. Key Country Dynamics
                           7.4.6.2. Competitive Scenario
                           7.4.6.3. Regulatory Framework
                           7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.4.7. South Korea
                           7.4.7.1. Key Country Dynamics
                           7.4.7.2. Competitive Scenario
                           7.4.7.3. Regulatory Framework
                           7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                   7.5. Latin America
                       7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.5.2. Brazil
                           7.5.2.1. Key Country Dynamics
                           7.5.2.2. Competitive Scenario
                           7.5.2.3. Regulatory Framework
                           7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.5.3. Mexico
                           7.5.3.1. Key Country Dynamics
                           7.5.3.2. Competitive Scenario
                           7.5.3.3. Regulatory Framework
                           7.5.3.4. Mexico Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.5.4. Argentina
                           7.5.4.1. Key Country Dynamics
                           7.5.4.2. Competitive Scenario
                           7.5.4.3. Regulatory Framework
                           7.5.4.4. Argentina Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                   7.6. MEA
                       7.6.1. MEA Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.6.2. South Africa
                           7.6.2.1. Key Country Dynamics
                           7.6.2.2. Competitive Scenario
                           7.6.2.3. Regulatory Framework
                           7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.6.3. Saudi Arabia
                           7.6.3.1. Key Country Dynamics
                           7.6.3.2. Competitive Scenario
                           7.6.3.3. Regulatory Framework
                           7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.6.4. UAE
                           7.6.4.1. Key Country Dynamics
                           7.6.4.2. Competitive Scenario
                           7.6.4.3. Regulatory Framework
                           7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
                       7.6.5. Kuwait
                           7.6.5.1. Key Country Dynamics
                           7.6.5.2. Competitive Scenario
                           7.6.5.3. Regulatory Framework
                           7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
                   8.1. Company Categorization
                   8.2. Strategy Mapping
                   8.3. Company Market Share Analysis, 2023
                   8.4. Company Profiles/Listing
                       8.4.1. United Therapeutics Corporation
                           8.4.1.1. Overview
                           8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.1.3. Product Benchmarking
                           8.4.1.4. Strategic Initiatives
                       8.4.2. Bayer AG
                           8.4.2.1. Overview
                           8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.2.3. Product Benchmarking
                           8.4.2.4. Strategic Initiatives
                       8.4.3. Gilead Sciences, Inc.
                           8.4.3.1. Overview
                           8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.3.3. Product Benchmarking
                           8.4.3.4. Strategic Initiatives
                       8.4.4. Johnson & Johnson Services Inc.
                           8.4.4.1. Overview
                           8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.4.3. Product Benchmarking
                           8.4.4.4. Strategic Initiatives
                       8.4.5. Viatris Inc.
                           8.4.5.1. Overview
                           8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.5.3. Product Benchmarking
                           8.4.5.4. Strategic Initiatives
                       8.4.6. GlaxoSmithKline
                           8.4.6.1. Overview
                           8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.6.3. Product Benchmarking
                           8.4.6.4. Strategic Initiatives
                       8.4.7. Novartis AG
                           8.4.7.1. Overview
                           8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.7.3. Product Benchmarking
                           8.4.7.4. Strategic Initiatives
                       8.4.8. Lupin Pharmaceuticals Inc.
                           8.4.8.1. Overview
                           8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.8.3. Product Benchmarking
                           8.4.8.4. Strategic Initiatives
                       8.4.9. Sun Pharmaceutical Industries, Inc.
                           8.4.9.1. Overview
                           8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.9.3. Product Benchmarking
                           8.4.9.4. Strategic Initiatives
                       8.4.10. Teva Pharmaceuticals Industries Ltd.
                           8.4.10.1. Overview
                           8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.10.3. Product Benchmarking
                           8.4.10.4. Strategic Initiatives

List of Tables

Table 1. List of secondary sources
Table 2. Average selling prices for approved PAH agents in the U.S. (2023)
Table 3. Summary of pipeline analysis for Early Phase I & Phase I PAH agents
Table 4. Summary of pipeline analysis for Phase II PAH agents
Table 5. Summary of pipeline analysis for Phase III PAH agents
Table 6. Summary of pipeline analysis for Phase IV PAH agents
Table 7. Summary of pipeline analysis for Phase IV PAH agents
Table 8. Global Pulmonary Arterial Hypertension (PAH) market, by Region, 2018 - 2030 (ASP in USD)
Table 9. Global Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 10. Global Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 11. Global Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 12. Global Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 13. Global Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 14. North America Pulmonary Arterial Hypertension market, by Country, 2018 - 2030 (USD Million)
Table 15. North America Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 16. North America Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 17. North America Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 18. North America Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 19. U.S. Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 20. U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 21. U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 22. Canada Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 23. Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 24. Canada Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 25. Europe Pulmonary Arterial Hypertension market, by country, 2018 - 2030 (USD Million)
Table 26. Europe Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 27. Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 28. Europe Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 29. Europe Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 30. U.K. Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 31. U.K. Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 32. U.K. Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 33. Germany Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 34. Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 35. Germany Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 36. France Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 37. France Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 38. France Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 39. Italy Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 40. Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 41. Italy Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 42. Spain Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 43. Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 44. Spain Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 45. Sweden Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 46. Sweden Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 47. Sweden Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 48. Denmark Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 49. Denmark Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 50. Denmark Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 51. Norway Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 52. Norway Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 53. Norway Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 54. Asia Pacific Pulmonary Arterial Hypertension market, by country, 2018 - 2030 (USD Million)
Table 55. Asia Pacific Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 56. Asia Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 57. Asia Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 58. Asia Pacific Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 59. China Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 60. China Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 61. China Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 62. Japan Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 63. Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 64. Japan Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 65. India Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 66. India Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 67. India Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 68. Australia Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 69. Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 70. Australia Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 71. South Korea Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 72. South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 73. South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 74. Thailand Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 75. Thailand Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 76. Thailand Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 77. Latin America Pulmonary Arterial Hypertension market, by country, 2018 - 2030 (USD Million)
Table 78. Latin America Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 79. Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 80. Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 81. Latin America Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 82. Brazil Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 83. Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 84. Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 85. Mexico Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 86. Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 87. Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 88. Argentina Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 89. Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 90. Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 91. MEA Pulmonary Arterial Hypertension market, by Country, 2018 - 2030 (USD Million)
Table 92. MEA Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 93. MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 94. MEA Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 95. MEA Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 96. South Africa Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 97. South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 98. South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 99. Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 100. Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 101. Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 102. UAE Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 103. UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 104. UAE Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 105. Kuwait Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 106. Kuwait Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 107. Kuwait Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Pulmonary Arterial Hypertension Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary research pattern
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling for Market share assessment
Fig. 9 Market formulation & validation
Fig. 10 Commodity flow analysis
Fig. 11 Market snapshot, 2023 (USD Million)
Fig. 12 Patent term expiry of the key Pulmonary Arterial Hypertension brands
Fig. 13 Ancillary Market analysis
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Consumer behavior analysis
Fig. 16 Market influencer analysis
Fig. 17 Market variables
Fig. 18 Market driver analysis
Fig. 19 Global prevalence of Pulmonary Arterial Hypertension
Fig. 20 Global geriatric population
Fig. 21 Market restraint analysis
Fig. 22 Market participant categorization
Fig. 23 Company Market position analysis: Heat map analysis
Fig. 24 Strategy mapping
Fig. 25 Market entry strategies
Fig. 26 Pulmonary Arterial Hypertension Market: Drug class dashboard
Fig. 27 Pulmonary Arterial Hypertension Market: Drug class movement analysis
Fig. 28 Prostacyclin pathway
Fig. 29 Prostacyclin and prostacyclin analogs Market, 2018 - 2030 (USD Million)
Fig. 30 Nitric oxide pathway
Fig. 31 SGC stimulators Market, 2018 - 2030 (USD Million)
Fig. 32 Endothelial pathway
Fig. 33 ERA Market, 2018 - 2030 (USD Million)
Fig. 34 PDE-5 Market, 2018 - 2030 (USD Million)
Fig. 35 Pulmonary Arterial Hypertension Market, by regions, 2018 - 2030 (USD Million)
Fig. 36 Pulmonary Arterial Hypertension Market: Type movement analysis, 2023 & 2030
Fig. 37 Pulmonary Arterial Hypertension Market Type outlook: Key takeaways
Fig. 38 Branded Market, 2018 - 2030 (USD Million)
Fig. 39 Generics Market, 2018 - 2030 (USD Million)
Fig. 40 Pulmonary Arterial Hypertension Market: Route of Administration movement analysis 2023 & 2030
Fig. 41 Pulmonary Arterial Hypertension Market Route of Administration outlook: Key takeaways
Fig. 42 Oral Market, 2018 - 2030 (USD Million)
Fig. 43 Intravenous/ subcutaneous Market, 2018 - 2030 (USD Million)
Fig. 44 Inhalational Market, 2018 - 2030 (USD Million)
Fig. 45 Intravenous/ subcutaneous Market, 2018 - 2030 (Units)
Fig. 46 Inhalational Market, 2018 - 2030 (Units)
Fig. 47 Regional Marketplace: Key takeaways
Fig. 48 Regional outlook, 2023 & 2030
Fig. 49 North America Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 50 U.S. Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 51 Canada Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 52 Europe Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 53 UK Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 54 Germany Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 55 France Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 56 Italy Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 57 Spain Pulmonary Arterial Hypertension Market, 2017- 2030 (USD Million)
Fig. 58 Sweden Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 59 Denmark Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 60 Norway Pulmonary Arterial Hypertension Market, 2017- 2030 (USD Million)
Fig. 61 Asia Pacific Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 62 Japan Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 63 China Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 64 India Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 65 South Korea Pulmonary Arterial Hypertension Market, 2017- 2030(USD Million)
Fig. 66 Australia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 67 Thailand Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 68 Latin America Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 69 Brazil Pulmonary Arterial Hypertension Market, 2017 - 2086 (USD Million)
Fig. 70 Mexico Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 71 Argentina Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 72 MEA Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 73 South Africa Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 74 Saudi Arabia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 75 UAE Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 76 Kuwait Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)